A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ponesimod | CAS 854107-55-4 - Request Quote

Picture of Ponesimod
SZ CAT No:SZ-P165001
CAS No
854107-55-4
Mol.F.
C23H25ClN2O4S
Mol.Wt.
461.0
Inv. Status
Synthesis on demand
Rel. CAS No2750141-37-6 (HCl salt) ; 2750141-38-7 (HBr salt)
Shipping Condition Room Temperature

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Ponesimod is chemically (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one. Ponesimod is supplied with detailed characterization data compliant with regulatory guideline. Ponesimod can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ponesimod.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 854107-55-4

Purchase 854107-55-4

Order 854107-55-4

Enquire 854107-55-4

price of 854107-55-4

854107-55-4 Supplier

854107-55-4 Manufacturer

854107-55-4 Exporter

buy high quality Ponesimod

Purchase Ponesimod

Ponesimod suppliers

Ponesimod manufacturers

Ponesimod price

Order Ponesimod

Enquire Ponesimod

Ponesimod cost

Ponesimod Supplier

Ponesimod Distributor

Ponesimod for Method Validation

Ponesimod Reference Standard

Ponesimod for ANDA Filing

Ponesimod for Forced Degradation Studies

Ponesimod Identification Standards

Ponesimod for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,